HUP0001382A3 - Extended release formulations of erythromycin derivatives - Google Patents

Extended release formulations of erythromycin derivatives

Info

Publication number
HUP0001382A3
HUP0001382A3 HU0001382A HUP0001382A HUP0001382A3 HU P0001382 A3 HUP0001382 A3 HU P0001382A3 HU 0001382 A HU0001382 A HU 0001382A HU P0001382 A HUP0001382 A HU P0001382A HU P0001382 A3 HUP0001382 A3 HU P0001382A3
Authority
HU
Hungary
Prior art keywords
extended release
release formulations
erythromycin derivatives
erythromycin
derivatives
Prior art date
Application number
HU0001382A
Other languages
English (en)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25278344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0001382(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of HUP0001382A2 publication Critical patent/HUP0001382A2/hu
Publication of HUP0001382A3 publication Critical patent/HUP0001382A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
HU0001382A 1997-04-11 1998-03-06 Extended release formulations of erythromycin derivatives HUP0001382A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/838,900 US6010718A (en) 1997-04-11 1997-04-11 Extended release formulations of erythromycin derivatives
PCT/US1998/004373 WO1998046239A1 (en) 1997-04-11 1998-03-06 Extended release formulations of erythromycin derivatives

Publications (2)

Publication Number Publication Date
HUP0001382A2 HUP0001382A2 (hu) 2000-09-28
HUP0001382A3 true HUP0001382A3 (en) 2001-08-28

Family

ID=25278344

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001382A HUP0001382A3 (en) 1997-04-11 1998-03-06 Extended release formulations of erythromycin derivatives

Country Status (29)

Country Link
US (1) US6010718A (hu)
EP (2) EP1340495B1 (hu)
JP (2) JP4394754B2 (hu)
KR (1) KR100484559B1 (hu)
CN (1) CN100408044C (hu)
AR (1) AR012358A1 (hu)
AT (1) ATE253371T1 (hu)
AU (1) AU737324B2 (hu)
BG (1) BG65188B1 (hu)
BR (1) BR9807974A (hu)
CA (1) CA2285266C (hu)
CO (1) CO4940403A1 (hu)
CZ (1) CZ294333B6 (hu)
DE (1) DE69819481T2 (hu)
DK (1) DK0973527T3 (hu)
ES (1) ES2205454T3 (hu)
HK (1) HK1027023A1 (hu)
HU (1) HUP0001382A3 (hu)
IL (3) IL131616A0 (hu)
NO (1) NO994946D0 (hu)
NZ (3) NZ537410A (hu)
PL (2) PL402949A1 (hu)
PT (1) PT973527E (hu)
SA (1) SA98190065B1 (hu)
SK (2) SK288127B6 (hu)
TR (2) TR199902149T2 (hu)
TW (1) TW576743B (hu)
WO (1) WO1998046239A1 (hu)
ZA (1) ZA982916B (hu)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU773863B2 (en) * 1997-04-11 2004-06-10 Bgp Products Operations Gmbh Extended release formulations of erythromycin derivatives
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
TR200000054A2 (tr) * 2000-01-05 2001-08-21 Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇ Klaritromisin içeren sürekli salım sağlayan tablet formülasyonları.
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
CZ20023167A3 (cs) * 2000-02-29 2003-10-15 Teva Pharmaceutical Industries Ltd. Způsob přípravy klaritromycinu a klaritromycinového meziproduktu, v podstatě prostého oximu a farmaceutický prostředek, který jej obsahuje
AU2001263812B2 (en) * 2000-03-28 2004-09-23 Sandoz Ag Granulated particles with masked taste
IN192748B (hu) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
WO2002038577A2 (en) * 2000-10-13 2002-05-16 Advancis Pharmaceuticals Extended release erythromycin derivatives
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US6790459B1 (en) 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
HUP0500791A2 (en) * 2001-08-29 2006-09-28 Ranbaxy Lab Ltd Controlled release formulation of clarithromycin or tinidazol
US6673369B2 (en) 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US20050249786A1 (en) * 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US7037523B2 (en) * 2001-11-02 2006-05-02 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
EP1485078B1 (en) * 2002-03-15 2012-09-26 Cypress Bioscience, Inc. Milnacipran for the treatment of irritable bowel syndrome
US20040052848A1 (en) * 2002-05-23 2004-03-18 Xiu-Xiu Cheng Biguanide formulations
AU2003245504A1 (en) * 2002-06-14 2003-12-31 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20040191302A1 (en) 2003-03-28 2004-09-30 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US9561182B2 (en) * 2003-08-22 2017-02-07 Cure Pharmaceutical Corporation Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
US8999372B2 (en) * 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
US20040131662A1 (en) 2003-11-12 2004-07-08 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
AU2004207578B2 (en) * 2003-01-28 2007-06-28 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
NZ543395A (en) * 2003-05-06 2008-04-30 Nirmal Mulye Controlled release formulation of erythromycin derivatives
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
CA2675724C (en) * 2003-06-16 2012-12-04 Andrx Pharmaceuticals, Llc Oral extended-release composition
US20050053658A1 (en) * 2003-09-09 2005-03-10 Venkatesh Gopi M. Extended release systems for macrolide antibiotics
US8313776B2 (en) * 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
US8313775B2 (en) * 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
JP2007502294A (ja) * 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
EP1658034A4 (en) * 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
WO2005023221A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Clarithromycin formulations having improved biovailability
JP2007513869A (ja) * 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
US20050084540A1 (en) * 2003-10-17 2005-04-21 Indranil Nandi Taste masking antibiotic composition
CN1874767A (zh) 2003-10-29 2006-12-06 惠氏公司 包含aplindore和其衍生物的缓释药物组合物
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
WO2005053656A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
CA2547773A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
RU2006119453A (ru) * 2003-12-04 2007-12-20 Пфайзер Продактс Инк. (Us) Получение посредством основанных на применении жидкостей способов лекарственные формы азитромицина с большим количеством частиц
WO2005053655A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Method for making pharmaceutical multiparticulates
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
WO2005053651A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
US7943585B2 (en) * 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
WO2005062898A2 (en) * 2003-12-24 2005-07-14 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
BRPI0508743A (pt) * 2004-03-24 2008-01-22 Lupin Ltd composição farmacêutica com uma liberação estendida de eritromicina ou um derivado da mesma, método para o uso de uma composição farmacêutica e processo para a preparação de uma composição farmacêutica
US20050260263A1 (en) * 2004-05-18 2005-11-24 Panion & Bf Biotech Inc. Sustained release formulation for sparingly soluble main drugs
KR101122096B1 (ko) * 2004-05-20 2012-03-15 주식회사종근당 쓴맛을 차폐하면서 우수한 용출률을 보이는클라리스로마이신의 약제학적 조성물 및 그의 제조 방법
KR100621342B1 (ko) * 2004-06-22 2006-09-18 (주)다산메디켐 클래리스로마이신-함유 약제학적 조성물 및 그의 제조방법
JP2008505124A (ja) * 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
JPWO2007126039A1 (ja) * 2006-04-28 2009-09-10 塩野義製薬株式会社 マクロライド系抗生物質の被覆製剤
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2007143507A2 (en) * 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
EP2283824B1 (en) 2009-07-30 2017-04-19 Special Products Line S.p.A. Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin
EP2671571A1 (en) 2012-06-05 2013-12-11 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-release formulations of clarithromycin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
ATE66143T1 (de) * 1985-01-11 1991-08-15 Abbott Lab Feste zubereitung mit langsamer freisetzung.
FR2585948B1 (fr) * 1985-08-06 1988-12-16 Pf Medicament Procede de fabrication de comprimes d'indometacine
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
US4925675A (en) 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
UA41995C2 (uk) * 1994-05-06 2001-10-15 Пфайзер Інк. Лікарська форма азитроміцину з контрольованим вивільненням ( варіанти ), спосіб її введення, спосіб її виготовлення і спосіб лікування інфекційних захворювань ссавців з її використанням ( варіанти )
JPH0995440A (ja) * 1995-09-29 1997-04-08 Roussel Morishita Kk 徐放性製剤およびその製造方法
US5919489A (en) * 1995-11-01 1999-07-06 Abbott Laboratories Process for aqueous granulation of clarithromycin
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter

Also Published As

Publication number Publication date
ATE253371T1 (de) 2003-11-15
TR200707263T2 (tr) 2008-01-21
WO1998046239A1 (en) 1998-10-22
IL131616A (en) 2013-03-24
SK138099A3 (en) 2000-04-10
DK0973527T3 (da) 2003-11-24
DE69819481D1 (de) 2003-12-11
CN100408044C (zh) 2008-08-06
EP1340495B1 (en) 2016-08-10
JP2009137988A (ja) 2009-06-25
AU6346398A (en) 1998-11-11
NO994946L (no) 1999-10-11
JP4394754B2 (ja) 2010-01-06
DE69819481T2 (de) 2004-08-26
NZ596215A (en) 2013-09-27
ZA982916B (en) 1998-10-09
NZ337120A (en) 2001-04-27
KR100484559B1 (ko) 2005-04-22
PL336142A1 (en) 2000-06-05
CZ294333B6 (cs) 2004-12-15
CZ347199A3 (cs) 2000-01-12
PT973527E (pt) 2004-01-30
TR199902149T2 (xx) 1999-12-21
AR012358A1 (es) 2000-10-18
BR9807974A (pt) 2000-03-08
JP5188994B2 (ja) 2013-04-24
CA2285266C (en) 2001-07-24
PL402949A1 (pl) 2013-04-15
TW576743B (en) 2004-02-21
AU737324B2 (en) 2001-08-16
EP0973527B1 (en) 2003-11-05
ES2205454T3 (es) 2004-05-01
NZ537410A (en) 2007-06-29
CO4940403A1 (es) 2000-07-24
HUP0001382A2 (hu) 2000-09-28
EP1340495A1 (en) 2003-09-03
JP2001524955A (ja) 2001-12-04
SK288127B6 (sk) 2013-10-02
SK288109B6 (sk) 2013-08-02
US6010718A (en) 2000-01-04
CA2285266A1 (en) 1998-10-22
IL131616A0 (en) 2001-01-28
CN1494911A (zh) 2004-05-12
BG65188B1 (bg) 2007-06-29
BG103862A (en) 2000-07-31
SA98190065B1 (ar) 2006-06-17
NO994946D0 (no) 1999-10-11
IL223035A0 (en) 2012-12-31
KR20010006251A (ko) 2001-01-26
HK1027023A1 (en) 2001-01-05
EP0973527A1 (en) 2000-01-26

Similar Documents

Publication Publication Date Title
IL131616A0 (en) Extended release formulations of erythromycin derivatives
IL149033A0 (en) Extended release formulations of erythromycin derivatives
EG24198A (en) Extended release formulation
IL138466A (en) Sustained release formulations containing macrolide compounds
PL339551A1 (en) Derivatives of rezorcin
GB9826662D0 (en) Controlled release formulation
PL337606A1 (en) Derivatives of erythromycin 9-oxime
PL341647A1 (en) Novel derivatives of erythromycin
HK1043043A1 (en) Controlled release formulation of divalproex sodium
IL135457A0 (en) Extended release formulation
PL340290A1 (en) 2-halogeno-6-0-substituted derivatives of ketolide
PL339137A1 (en) 6,9-bridged derivatives of erythromycin
PL340253A1 (en) 6,11-bridged derivatives of erythromycin
IL119142A0 (en) Slow release formulations of pesticides
ZA9810710B (en) Sustained release formulations comprising alpha-glucosidase-inhibitors
PL334769A1 (en) Derivatives of 5-aroylnaphtene
EP1044985A4 (en) ERYTHROMYCIN DERIVATIVES
ZA985064B (en) Derivatives of pentaerythrits
SI0973527T1 (en) Extended release formulations of clarithromycin
GB9816563D0 (en) Controlled release formulations
IL151450A0 (en) Extended release formulation of venlafazine hydrochloride
PL319982A1 (en) N3-aminoalkyl derivatives of (z)-5-arylidenehydantoin
ZA965334B (en) Controlled release formulations of ranitidine
ZA989845B (en) 2-halo-6-O-substituted ketolide derivatives
SI1027362T1 (sl) 2-halo-6-O-substituirani derivati ketolidov

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished